1 / 6

Memantine in Moderate to Severe Alzheimer’s Disease

Memantine in Moderate to Severe Alzheimer’s Disease. Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S. H., and Möbius H. J. New England Journal of Medicine 2003, 348: 1333-1341. Study Design. No. of patients N = 252 (outpatients) Diagnosis Probable Alzheimer’s disease

irma-brennan
Télécharger la présentation

Memantine in Moderate to Severe Alzheimer’s Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Memantine in Moderate to Severe Alzheimer’s Disease Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S. H., and Möbius H. J. New England Journal of Medicine 2003, 348: 1333-1341

  2. Study Design No. of patients N = 252 (outpatients) Diagnosis Probable Alzheimer’s disease Design Double-blind, randomized, placebo- controlled, multicenter study Age  50 years (mean 76) Severity MMSE 3 – 14 (mean 7.9) GDS 5 – 6 FAST  6a Dose; duration 20 mg memantine/day; 28 weeks Primary efficacy Global: CIBIC-plusparameters Function: ADCS-ADLsev Secondary efficacy Cognition: SIB, Behavior: NPI parameters MMSE, FAST, GDS, Resource Utilisation in Dementia (RUD) Reisberg et al., N Engl J Med 2003

  3. 3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0 N = 126 both groups N = 107 * N = 97  Memantine (20 mg/day)  Placebo N = 105 N = 84 0 12 28 Significant Benefit of Memantine in Clinical Global Impression (CIBIC-Plus) OC analysis 4.0 = no change Improvement CIBIC-Plus global score Worsening Week *p = 0.025 versus placebo Reisberg et al., N Engl J Med 2003

  4. N=119 1 0 -1 -2 -3 -4 -5 -6 -7 N = 107 N = 126 both groups * N = 97 N = 117 N = 106  Memantine (20 mg/day)  Placebo N = 84 0 4 12 28 Significant Benefit of Memantine in Activities of Daily Living OC analysis Mean change from baseline Improvement ADCS-ADLsev score difference Worsening Week *p = 0.003 versus placebo Reisberg et al., N Engl J Med 2003

  5. 4 2 0 -2 -4 -6 -8 -10 -12 N = 119 N = 107 N = 126 both groups * N = 117 N = 97  Memantine (20 mg/day)  Placebo N = 106 N = 83 0 4 12 28 Significant Benefit on Cognition (Severe Impairment Battery) OC analysis Mean change from baseline Improvement SIB score difference Worsening Week *p = 0.002 versus placebo Reisberg et al., N Engl J Med 2003

  6. Summary • Statistically significant benefit of memantine compared to placebo on three independent levels: • clinical global impression • functional capacity in activities of daily living • cognition in moderate to severe Alzheimer‘s disease • Good safety and tolerability of memantine Reisberg et al., N Engl J Med 2003

More Related